

Appendix 19: Clinical evidence forest plots


Service-level interventions.....	3
Collaborative care versus everything	3
Collaborative care – subgroup analysis by comparison (standard care, enhanced standard care).....	16
Collaborative care – sensitivity analysis: ICC calculations.....	25
Collaborative care – sensitivity analysis: recruited for comorbid physical health condition.....	34
Other service-level interventions versus standard care	41
Psychological and psychosocial interventions	44
Physical activity versus standard care.....	44
Peer (self-help) support versus standard care	48
Peer (self-help) support versus group based cognitive and behavioural interventions	50
Guided self-help based on cognitive and behavioural principles versus standard care	51
Individual guided self-help based on McMaster model of family functioning versus standard care	52
Health education versus standard care	53
Relaxation training versus standard care	54
Social support versus standard care	56
Individual-based cognitive and behavioural interventions versus standard care.....	56
Individual-based cognitive and behavioural interventions versus counselling	59
Group-based cognitive and behavioural interventions versus standard care.....	61
Group-based cognitive and behavioural interventions versus other (peer self-help support and health education)	66
Counselling versus standard care	67
Group existential therapy versus active control	68
Combination interventions.....	70
Psychological/ psychosocial (psych) interventions plus pharmacological interventions (pharm) versus psychological/ psychosocial intervention alone.....	70
Psychological/ psychosocial interventions (psych) plus pharmacological interventions (pharm) versus pharmacological interventions alone.....	72
Psychological/ psychosocial versus pharmacological interventions.....	73
Psychological/ psychosocial interventions (psych) versus pharmacological interventions (pharm).....	73
Pharmacological interventions	74
SSRIs versus placebo	74

TCAs versus placebo	93
Third-generation drugs versus placebo.....	100
Mianserin versus placebo	103
Trazodone versus placebo	106
Any antidepressant versus placebo – sensitivity analysis removing non-blinded studies	107
Any antidepressant versus placebo – sensitivity analysis removing subthreshold studies	110
Any antidepressant versus placebo – subgroup analysis: HAM-D only.....	113
SSRIs versus TCAs	115
SSRI versus placebo – sensitivity analysis removing non-blinded and subthreshold studies.....	125
TCAs versus placebo – sensitivity analysis removing non-blinded and subthreshold studies	129


Service-level interventions

Collaborative care versus everything


Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 20 Mortality




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 30 Depression outcome. 1. Non-response (<50% improvement) - sensitivity analysis




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 32 Depression outcome 2. Non-remission (scoring above cut-off, for example >7 on HAM-D)




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 33 Depression outcome 3. Diagnosis (at follow-up)




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 34 Depression outcome 4.Continuous measures depression rating scale (Change score)




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 40 Physical health outcome: 1. Sheehan disability score




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 41 Physical health outcome: 2. Pain intensity (Brief Pain Inventory, author defined scale)




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 42 Physical health outcome: 3. Interference with daily activities




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 43 Physical health outcome: 4. Pain interferes with activity




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 44 Physical health outcome: 5. Haemoglobin values




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 45 Physical health outcome 6. Non-adherence to physical health treatment




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 46 Physical health outcome: 7. BMI




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 47 Physical health outcome: 8. Fatigue




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 49 Physical health outcome/ QoL: 1. General physical wellbeing/ functioning (SF-12 physical etc)




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 50 Physical health outcome/ QoL: 2. General physical wellbeing/ functioning (Change scores)




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 55 Quality of Life 1. General QoL scales (Euroqol, 0-10 rating scale etc.)




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 56 Quality of Life 2. No. QALWs gained (signs reversed)




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 60 Service use/ Process of care: 1. Did not receive a consultation / specified number of mental health visits




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 61 Service use/ Process of care: 2. Number of psychiatric outpatient visits




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 62 Service use/ Process of care: 3. Readmission




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 63 Service use/ Process of care: 4. Any visit to A&E




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 64 Service use/ process of care : 5. Not receiving any depression treatment (antidepressants or psychosocial)




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 65 Service use/ process of care : 6. Not receiving antidepressant medication




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 66 Service use/ process of care : 7. Not receiving psychosocial interventions




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 67 Service use / Process of care (64-66 combined)




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 70 Treatment acceptability - leaving the study early for any reason



Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 80 Satisfaction with service - not satisfied with treatment/care




Review: DCHP - Service
 Comparison: 01 Collaborative care versus everything (WCS analysis)
 Outcome: 81 Non-adherence to antidepressant medication




Collaborative care - subgroup analysis by comparison (standard care, enhanced standard care)


Review: DCHP - Service
 Comparison: 02 Collaborative care vs. everything (WCS analysis) - subgroup by comparison
 Outcome: 20 Mortality




Review: DCHP - Service
 Comparison: 02 Collaborative care versus everything (WCS analysis) - subgroup by comparison
 Outcome: 31 Depression outcome: 1. Non-Response (<50% improvement) - removing outlier




Review: DCHP - Service
 Comparison: 02 Collaborative care versus everything (WCS analysis) - subgroup by comparison
 Outcome: 32 Depression outcome: 2. Non-remission (scoring above cut-off, for example >7 on HAM-D) - removed outlier




Review: DCHP - Service
 Comparison: 02 Collaborative care versus everything (WCS analysis) - subgroup by comparison
 Outcome: 34 Depression outcome: 4.Continuous measures depression rating scale (Change score)




Review: DCHP - Service
 Comparison: 02 Collaborative care versus everything (WCS analysis) - subgroup by comparison
 Outcome: 41 Physical health outcome: 2. Pain intensity (Brief Pain Inventory, author defined scale)




Review: DCHP - Service
 Comparison: 02 Collaborative care versus everything (WCS analysis) - subgroup by comparison
 Outcome: 48 Physical health outcome/ QoL: 1. General physical well-being/ functioning (SF-12 physical etc)




Review: DCHP - Service
 Comparison: 02 Collaborative care versus everything (WCS analysis) - subgroup by comparison
 Outcome: 49 Physical health outcome/ QoL: 2. General physical well-being/ functioning (Change scores)




Review: DCHP - Service
 Comparison: 02 Collaborative care versus everything (WCS analysis) - subgroup by comparison
 Outcome: 65 Service use/ process of care : 6. Not receiving antidepressant medication




Review: DCHP - Service
 Comparison: 02 Collaborative care versus everything (WCS analysis) - subgroup by comparison
 Outcome: 67 Service use / Process of care (64-66 combined)



Review: DCHP - Service
 Comparison: 02 Collaborative care versus everything (WCS analysis) - subgroup by comparison
 Outcome: 70 Treatment acceptability - leaving the study early for any reason




Review: DCHP - Service
 Comparison: 02 Collaborative care versus everything (WCS analysis) - subgroup by comparison
 Outcome: 80 Satisfaction with service - not satisfied with treatment/care




Collaborative care – sensitivity analysis: ICC calculations


Review: DCHP - Service
 Comparison: 03 Collaborative care versus everything (WCS analysis) - sensitivity analysis based on ICC
 Outcome: 20 Mortality




Review: DCHP - Service
 Comparison: 03 Collaborative care versus everything (WCS analysis) - sensitivity analysis based on ICC
 Outcome: 30 Depression outcome: 1. Non-response (<50% improvement) - outlier removed




Review: DCHP - Service
 Comparison: 03 Collaborative care versus everything (WCS analysis) - sensitivity analysis based on ICC
 Outcome: 32 Depression outcome 2. Non-remission (scoring above cut-off for example, >7 on HAM-D) - outlier removed




Review: DCHP - Service
 Comparison: 03 Collaborative care versus everything (WCS analysis) - sensitivity analysis based on ICC
 Outcome: 34 Depression outcome: 4.Continuous measures depression rating scale (Change score)




Review: DCHP - Service
 Comparison: 03 Collaborative care versus everything (WCS analysis) - sensitivity analysis based on ICC
 Outcome: 49 Physical health outcome/ QoL: 2. General physical well-being/ functioning (Change scores)




Review: DCHP - Service
 Comparison: 03 Collaborative care versus everything (WCS analysis) - sensitivity analysis based on ICC
 Outcome: 60 Service use/ Process of care: 1. Did not receive a consultation / specified number of mental health visits




Review: DCHP - Service
 Comparison: 03 Collaborative care versus everything (WCS analysis) - sensitivity analysis based on ICC
 Outcome: 65 Service use/ process of care : 6. Not receiving antidepressant medication



Review: DCHP - Service
 Comparison: 03 Collaborative care versus everything (WCS analysis) - sensitivity analysis based on ICC
 Outcome: 67 Service use / Process of care (64-66 combined)




Review: DCHP - Service
 Comparison: 03 Collaborative care versus everything (WCS analysis) - sensitivity analysis based on ICC
 Outcome: 80 Satisfaction with service - not satisfied with treatment/care




Collaborative care – sensitivity analysis: recruited for comorbid physical health condition


Review: DCHP - Service
 Comparison: 05 Collaborative care versus everything (WCS analysis) - sensitivity analysis (recruited for chronic condition)
 Outcome: 20 Mortality




Review: DCHP - Service
 Comparison: 05 Collaborative care versus everything (WCS analysis) - sensitivity analysis (recruited for chronic condition)
 Outcome: 30 Depression outcome: 1. Non-response (<50% improvement) - sensitivity analysis




Review: DCHP - Service
 Comparison: 05 Collaborative care versus everything (WCS analysis) - sensitivity analysis (recruited for chronic condition)
 Outcome: 32 Depression outcome: 2. Non-remission (scoring above cut off e.g. >7 on HAM-D)




Review: DCHP - Service
 Comparison: 05 Collaborative care versus everything (WCS analysis) - sensitivity analysis (recruited for chronic condition)
 Outcome: 34 Depression outcome: 4.Continuous measures depression rating scale (Change score)




Review: DCHP - Service
 Comparison: 05 Collaborative care versus everything (WCS analysis) - sensitivity analysis (recruited for chronic condition)
 Outcome: 41 Physical health outcome: 2. Pain intensity (Brief Pain Inventory, author defined scale)




Review: DCHP - Service
 Comparison: 05 Collaborative care versus everything (WCS analysis) - sensitivity analysis (recruited for chronic condition)
 Outcome: 49 Physical health outcome/ QoL: 1. General physical well-being/ functioning (SF-12 physical etc)



Review: DCHP - Service
 Comparison: 05 Collaborative care versus everything (WCS analysis) - sensitivity analysis (recruited for chronic condition)
 Outcome: 50 Physical health outcome/ QoL: 2. General physical well-being/ functioning (Change scores)




Review: DCHP - Service
 Comparison: 05 Collaborative care versus everything (WCS analysis) - sensitivity analysis (recruited for chronic condition)
 Outcome: 70 Treatment acceptability - leaving the study early for any reason




Other service-level interventions versus standard care


Review: DCHP - Service
 Comparison: 20 Other service-level interventions (multidisciplinary teams, consultation-liaison) versus standard care (WCS)
 Outcome: 20 Mortality




Review: DCHP - Service
 Comparison: 20 Other service level interventions (multidisciplinary teams, consultation-liaison) versus standard care (WCS)
 Outcome: 33 Depression outcome: 3. Diagnosis (at follow-up)




Review: DCHP - Service
 Comparison: 20 Other service level interventions (multidisciplinary teams, consultation-liaison) versus standard care (WCS)
 Outcome: 34 Depression outcome: 4. Continuous measures depression rating scale (Change score)



Review: DCHP - Service
 Comparison: 20 Other service level interventions (multidisciplinary teams, consultation-liaison) versus standard care (WCS)
 Outcome: 48 Physical health outcome/ QoL: 1. General physical well-being/ functioning (SF-12 physical etc)




Review: DCHP - Service
 Comparison: 20 Other service level interventions (multidisciplinary teams, consultation-liaison) versus standard care (WCS)
 Outcome: 70 Treatment acceptability - leaving the study early for any reason




Psychological and psychosocial interventions

Physical activity versus standard care


Review: DCHP: Physical activity
 Comparison: 01 Physical activity versus standard (std) care
 Outcome: 01 Depression (end of treatment)




Review: DCHP: Physical activity
 Comparison: 01 Physical activity versus standard care
 Outcome: 02 Depression (change score: end of treatment)




Review: DCHP: Physical activity
 Comparison: 01 Physical activity versus standard care
 Outcome: 03 Non-remission (below cut-off)




Review: DCHP: Physical activity
 Comparison: 01 Physical activity versus standard care
 Outcome: 04 Non-remission (6-month follow-up)



Review: DCHP: Physical activity
 Comparison: 01 Physical activity versus standard care
 Outcome: 07 Quality of life (end of treatment)




Review: DCHP: Physical activity
 Comparison: 01 Physical activity versus standard care
 Outcome: 08 Physical health outcomes (end of treatment)




Peer (self-help) support versus standard care


Review: DCHP: Peer (self-help) support
 Comparison: 01 Peer (self-help) support versus standard care
 Outcome: 01 Depression (end of treatment)



Review: DCHP: Peer (self-help) support
 Comparison: 01 Peer (self-help) support versus standard care
 Outcome: 03 CES-D (6-month follow-up)




Review: DCHP: Peer (self-help) support
 Comparison: 01 Peer (self-help) support versus standard care
 Outcome: 04 Physical Health Outcomes: HIV-1 RNA viral load




Peer (self-help) support versus group based cognitive and behavioural interventions

Review: DCHP: Peer (self-help) support
 Comparison: 02 Peer (self-help) support versus group based cognitive and behavioural interventions
 Outcome: 01 Depression (end of treatment)




Review: DCHP: Peer (self-help) support
 Comparison: 02 Peer (self-help) support versus group based cognitive and behavioural interventions
 Outcome: 02 Depression (follow-up)




Guided self-help based on cognitive and behavioural principles versus standard care

Review: DCHP: Guided self-help
 Comparison: 01 Guided self-help based on cognitive behavioural principles versus standard care
 Outcome: 01 Depression (end of treatment)




Review: DCHP: Guided self-help (not separating comparison)
 Comparison: 01 Guided self-help based on cognitive behavioural principles versus standard care
 Outcome: 02 Physical health outcome: visual functioning questionnaire




Individual guided self-help based on McMaster model of family functioning versus standard care

Review: DCHP: Individual guided self-help
 Comparison: 02 Individual guided self-help based on McMaster model of family functioning principles versus standard care
 Outcome: 01 Non-remission (below cut-off)




Review: DCHP: Individual guided self-help
 Comparison: 02 Individual guided self-help based on McMaster model of family functioning principles versus standard care
 Outcome: 02 Non-response (<50% reduction from baseline)




Health education versus standard care


Review: DCHP: Health Education
 Comparison: 01 Health education versus standard care
 Outcome: 01 BDI 21 item: self-report (end of treatment)



Review: DCHP: Health Education
 Comparison: 01 Health education versus standard care
 Outcome: 02 BDI 21 item: self-report (follow-up)




Review: DCHP: Health Education
 Comparison: 02 Health education plus other psychosocial component versus standard care
 Outcome: 01 Depression (end of treatment)




Relaxation training versus standard care

Review: DCHP - Relaxation training
 Comparison: 01 Relaxation versus standard care
 Outcome: 01 Depression (Change scores)




Review: DCHP - Relaxation training
 Comparison: 01 Relaxation versus standard care
 Outcome: 03 Health related quality of life (end of treatment)




Social support versus standard care

Review: DCHP: Social Support
 Comparison: 01 Social Support versus standard care
 Outcome: 01 CES-D: self-report (end of treatment)




Individual-based cognitive and behavioural interventions versus standard care


Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 01 Individual-based cognitive and behavioural intervention versus standard care
 Outcome: 01 Depression (end of treatment)




Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 01 Individual-based cognitive and behavioural intervention versus standard care
 Outcome: 13 Non-remission (below cut-off)



Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 01 Individual-based cognitive and behavioural intervention versus standard care
 Outcome: 03 Depression (end of treatment) - sensitivity analysis - participants recruited for depression




Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 01 Individual-based cognitive and behavioural intervention versus standard care
 Outcome: 04 Depression (follow-up)



Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 01 Individual-based cognitive and behavioural intervention versus standard care
 Outcome: 11 QoL - QLQ-C33 (end of treatment)




Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 01 Individual-based cognitive and behavioural intervention versus standard care
 Outcome: 12 Physical health outcome




Individual-based cognitive and behavioural interventions versus counselling


Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 02 Individual-based cognitive and behavioural intervention versus counselling
 Outcome: 01 Depression (end of treatment)



Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 02 Individual-based cognitive and behavioural intervention versus counselling
 Outcome: 02 Depression (change score: end of treatment)




Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 02 Individual-based cognitive and behavioural intervention versus counselling
 Outcome: 05 Depression (follow-up)




Group-based cognitive and behavioural interventions versus standard care


Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 03 Group-based cognitive and behavioural intervention versus standard care
 Outcome: 01 Depression (end of treatment)




Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 03 Group-based cognitive and behavioural intervention versus standard care
 Outcome: 06 Non-remission (below cut off)




Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 03 Group-based cognitive and behavioural intervention versus standard care
 Outcome: 07 Non-response (<50% reduction from baseline)




Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 03 Group-based cognitive and behavioural intervention versus standard care
 Outcome: 05 Depression (follow-up)




Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 03 Group-based cognitive and behavioural intervention versus standard care
 Outcome: 02 Depression (end of treatment) - sensitivity analysis (removed outlier)




Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 03 Group-based cognitive and behavioural intervention versus standard care
 Outcome: 04 Depression (end of treatment) - sensitivity analysis - participants recruited for depression



Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 03 Group-based cognitive and behavioural intervention versus standard care
 Outcome: 03 Depression (end of treatment) - sub-group analysis by aim of intervention




Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 03 Group-based cognitive and behavioural intervention versus standard care
 Outcome: 15 QoL - SF-30: self-report (end of treatment)




Group-based cognitive and behavioural interventions versus other (peer self-help support and health education)

Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 06 Group-based cognitive and behavioural intervention versus other (peer self-help support and health education)
 Outcome: 01 Depression (end of treatment)




Review: DCHP: Cognitive and Behavioural Interventions
 Comparison: 06 Group-based cognitive and behavioural intervention versus other (peer self-help support and health education)
 Outcome: 02 Depression at follow-up (6-months of less)




Counselling versus standard care

Review: DCHP: Counselling
 Comparison: 01 Counselling versus standard care
 Outcome: 01 BDI: self report (end of treatment)




Group existential therapy versus active control


Review: DCHP: Group Existential Therapy
 Comparison: 01 Group existential therapy
 Outcome: 01 Depression (end of treatment)



Review: DCHP: Group Existential Therapy
 Comparison: 01 Group existential therapy
 Outcome: 03 Depression (Change score at end of treatment)




Review: DCHP: Group Existential Therapy
 Comparison: 01 Group existential therapy
 Outcome: 05 Non-remission (still meeting diagnosis of depression) - end of treatment




Combination interventions

Psychological/psychosocial (psych) interventions plus pharmacological interventions (pharm) versus psychological/psychosocial intervention alone


Review: DCHP: Psych + Pharm
 Comparison: 01 SSRIs + psych versus psych
 Outcome: 01 Depression (HAM-D)




Review: DCHP: Psych + Pharm
 Comparison: 01 SSRIs + psych versus psych
 Outcome: 02 Depression (BDI)



Review: DCHP: Psych + Pharm
 Comparison: 02 TCAs + psych versus psych
 Outcome: 01 Depression (HAM-D)




Review: DCHP: Psych + Pharm
 Comparison: 02 TCAs + psych versus psych
 Outcome: 02 Depression (BDI)




Psychological/psychosocial interventions (psych) plus pharmacological interventions (pharm) versus pharmacological interventions alone

Review: DCHP: Psych + Pharm
 Comparison: 03 SSRI + Psych versus SSRI
 Outcome: 01 Depression (HAM-D)




Review: DCHP: Psych + Pharm
 Comparison: 03 SSRI + Psych versus SSRI
 Outcome: 02 Depression (BDI)




Psychological/psychosocial versus pharmacological interventions

Psychological/psychosocial interventions (psych) versus pharmacological interventions (pharm)

Review: DCHP: Psych + Pharm
 Comparison: 04 Psych versus SSRIs
 Outcome: 01 Depression (HAM-D)




Review: DCHP: Psych + Pharm
 Comparison: 04 Psych versus SSRIs
 Outcome: 02 Depression (BDI)




Pharmacological interventions

SSRIs versus placebo


Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus PLACEBO
 Outcome: 01 Leaving the Study early: Any reason




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 02 Leaving the study early: Lack of efficacy




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 03 Leaving the Study early: Due to adverse events




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 10 Mortality




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 30 Depression: 1. Not achieving success/ remission (reaching a specified cut-off) - patient rated




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 31 Depression: 1. Not achieving success/ remission (reaching a specified cut-off) - observer rated




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 32 Depression: 2. Non-response (not achieving 50% reduction from baseline) - patient rated e.g. BDI




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 33 Depression: 2. Non-response (not achieving 50% reduction from baseline) - observer rated e.g. HAMD, MADRS




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 34 Depression: 3. Patient-rated Continuous measures




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 35 Depression: 4. Observer-rated Continuous measures




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 36 Depression: 5. Recurrence/ Relapse of depression




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 40 Mental State: Continuous measures 1. Hamilton Anxiety Scale




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 41 Mental State: Continuous measures 2. Global symptom measures e.g CGI, SCL-90, POMS




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 50 QoL: 1. Continuous measures e.g. SQOLI, FACT-G




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 51 Physical outcome / QoL - General physical functioning/ well-being (SF-36 physical component)




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 52 Physical health outcome. 1. Fatigue




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 53 Physical health outcome: 2. Asthma Control Questionnaire




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 54 Physical health outcome: 3. Physical activity - PFSI, ADLI, functional independence




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 55 Physical health outcome: 4. Exercise tolerance test 6MWD (signs reversed)




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 56 Physical health outcome: 5. GHbA1c (%)




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 57 Physical health outcome: 6. Serum Glucose (mmol/l)



Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 58 Physical health outcome: 7. Serum C-peptide (nmol/l)




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 59 Physical health outcome: 8. BMI




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 60 Physical health outcome: 9. Medication compliance




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 61 Physical health outcome: 10. Cognitive deficits (PDQ, MMSE)




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 70 AE: 1. Reported at least 1 adverse event




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 71 AE: 2. Death or cardiac rehospitalisation



Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 72 AE: 3. Continuous measures PRD-III




Review: DCHP - Pharm - by drug class
 Comparison: 02 SSRIs versus placebo
 Outcome: 73 Treatment tolerance: 1. Observer-rated continuous measures




TCAs versus placebo


Review: DCHP - Pharm - by drug class
 Comparison: 03 TCAs versus placebo
 Outcome: 01 Leaving the study early: Any reason




Review: DCHP - Pharm - by drug class
 Comparison: 03 TCAs versus placebo
 Outcome: 02 Leaving due to adverse events




Review: DCHP - Pharm - by drug class
 Comparison: 03 TCAs versus placebo
 Outcome: 05 Mortality




Review: DCHP - Pharm - by drug class
 Comparison: 03 TCAs versus placebo
 Outcome: 10 Depression: 1. Non-response (<50% improvement) - observer rated




Review: DCHP - Pharm - by drug class
 Comparison: 03 TCAs versus placebo
 Outcome: 11 Depression: 2. Not achieving success/ remission (reaching a specified cut-off) Patient-rated




Review: DCHP - Pharm - by drug class
 Comparison: 03 TCAs versus placebo
 Outcome: 12 Depression: 3. Patient-rated continuous measures (End of treatment)




Review: DCHP - Pharm - by drug class
 Comparison: 03 TCAs versus placebo
 Outcome: 20 Physical outcome / QoL - General physical functioning/ well-being (SF-36 etc)




Review: DCHP - Pharm - by drug class
 Comparison: 03 TCAs versus placebo
 Outcome: 25 Physical health outcome: 1. Symptom anxiety PRAS




Review: DCHP - Pharm - by drug class
 Comparison: 03 TCAs versus placebo
 Outcome: 26 Physical health outcome: 2. Somatic symptoms




Review: DCHP - Pharm - by drug class
 Comparison: 03 TCAs versus placebo
 Outcome: 27 Physical health outcome: 3. Symptoms associated with breathing



Review: DCHP - Pharm - by drug class
 Comparison: 03 TCAs versus placebo
 Outcome: 28 Physical health outcome: 4. Physical activity (HVID, ADL)




Review: DCHP - Pharm - by drug class
 Comparison: 03 TCAs versus placebo
 Outcome: 29 Physical health outcome: 5. Cognitive function (MMSE)




Third-generation drugs versus placebo


Review: DCHP - Pharm - by drug class
 Comparison: 04 3rd generation ADs versus placebo
 Outcome: 01 Leaving the study early: any reason




Review: DCHP - Pharm - by drug class
 Comparison: 04 3rd generation ADs versus placebo
 Outcome: 21 Depression: 1. Not achieving success/ remission (reaching a specified cut-off) - observer rated




Review: DCHP - Pharm - by drug class
 Comparison: 04 3rd generation ADs versus placebo
 Outcome: 22 Depression: 2. Non-response (<50% reduction) - observer rated




Review: DCHP - Pharm - by drug class
 Comparison: 04 3rd generation ADs versus placebo
 Outcome: 23 Depression 3: Continuous measures patient rated, e.g, BDI, HADS GDS



Review: DCHP - Pharm - by drug class
 Comparison: 04 3rd generation ADs versus placebo
 Outcome: 24 Depression: 4. Observer-rated continuous measures




Review: DCHP - Pharm - by drug class
 Comparison: 04 3rd generation ADs versus placebo
 Outcome: 30 Physical outcome / QoL - General physical functioning/ well-being (SF-36 etc)




Mianserin versus placebo


Review: DCHP - Pharm - by drug class
 Comparison: 05 Mianserin versus placebo
 Outcome: 01 Leaving the study early: Any reason




Review: DCHP - Pharm - by drug class
 Comparison: 05 Mianserin versus placebo
 Outcome: 02 Leaving the study early due to lack of efficacy




Review: DCHP - Pharm - by drug class
 Comparison: 05 Mianserin versus placebo
 Outcome: 03 Leaving the Study early: Due to adverse events




Review: DCHP - Pharm - by drug class
 Comparison: 05 Mianserin versus placebo
 Outcome: 04 Depression: 2. Non-response (not achieving 50% reduction from baseline) - observer rated e.g. HAMD, MADRS




Review: DCHP - Pharm - by drug class
 Comparison: 05 Mianserin versus placebo
 Outcome: 05 Depression: 3. Patient-rated continuous measures




Review: DCHP - Pharm - by drug class
 Comparison: 05 Mianserin vs. placebo
 Outcome: 06 Depression: 4. Observer-rated continuous measures



Review: DCHP - Pharm - by drug class
 Comparison: 05 Mianserin versus placebo
 Outcome: 07 Mental State: Continuous measures 2. Global symptom measures e.g CGI, SCL-90, POMS




Review: DCHP - Pharm - by drug class
 Comparison: 05 Mianserin versus placebo
 Outcome: 08 AE: 1. Reported at least 1 adverse event




Trazodone versus placebo


Review: DCHP - Pharm - by drug class
 Comparison: 06 Trazodone versus placebo
 Outcome: 01 Depression: 1. Continuous measures - patient rated



Review: DCHP - Pharm - by drug class
 Comparison: 06 Trazodone versus placebo
 Outcome: 02 Physical health outcome: 1. Physical activities (ADL)




Review: DCHP - Pharm - by drug class
 Comparison: 07 Psychostimulants versus placebo
 Outcome: 01 Mean depression




Any antidepressant versus placebo – sensitivity analysis removing non-blinded studies


Review: DCHP - Pharm - by drug class
 Comparison: 11 Any antidepressant versus placebo (sensitivity analyses)
 Outcome: 04 Leaving the study early: Due to adverse events



Review: DCHP - Pharm - by drug class
 Comparison: 11 Any antidepressant versus placebo (sensitivity analyses)
 Outcome: 31 Depression: 1. Not achieving success/ remission (reaching a specified cut-off) - observer rated




Review: DCHP - Pharm - by drug class
 Comparison: 11 Any antidepressant versus placebo (sensitivity analyses)
 Outcome: 33 Depression: 2. Non-response (not achieving 50% reduction from baseline) - observer rated e.g. HAMD, MADRS




Any antidepressant versus placebo – sensitivity analysis removing subthreshold studies

See next page.

Review: DCHP - Pharm - by drug class
 Comparison: 11 Any antidepressant versus placebo (sensitivity analyses)
 Outcome: 34 Depression: 3. Patient-rated continuous measures




Review: DCHP - Pharm - by drug class
 Comparison: 11 Any antidepressant versus placebo (sensitivity analyses)
 Outcome: 35 Depression: 4. Observer-rated Continuous measures




Any antidepressant versus placebo - subgroup analysis: HAM-D only

Review: DCHP - Pharm - by drug class
 Comparison: 11 Any antidepressant versus placebo (sensitivity analyses)
 Outcome: 36 Depression: 4. Observer-rated continuous measures (HAM-D only)




Review: DCHP - Pharm - by drug class
 Comparison: 11 Any antidepressant versus placebo (sensitivity analyses)
 Outcome: 37 Depression: 4. Observer-rated continuous measures (HAM-D only - removing non double-blind and sub-threshold)




SSRIs versus TCAs

See next page.


Review: DCHP - Pharm - by drug class
 Comparison: 20 Head-to-head SSRI versus TCA
 Outcome: 20 Leaving the study early - any reason




Review: DCHP - Pharm - by drug class
 Comparison: 20 Head-to-head SSRI versus TCA
 Outcome: 21 Leaving study early due to adverse events




Review: DCHP - Pharm - by drug class
 Comparison: 20 Head-to-head SSRI versus TCA
 Outcome: 22 Leaving study early due to adverse cardiac events




Review: DCHP - Pharm - by drug class
 Comparison: 20 Head-to-head SSRI versus TCA
 Outcome: 23 Leaving the study early: Due to lack of efficacy




Review: DCHP - Pharm - by drug class
 Comparison: 20 Head-to-head SSRI versus TCA
 Outcome: 30 Depression: 1. Remission (below cut-off)




Review: DCHP - Pharm - by drug class
 Comparison: 20 Head-to-head SSRI versus TCA
 Outcome: 31 Depression: 2. Non-response (<50% reduction)




Review: DCHP - Pharm - by drug class
 Comparison: 20 Head-to-head SSRI versus TCA
 Outcome: 32 Depression: 3. Continuous measures




Review: DCHP - Pharm - by drug class
 Comparison: 20 Head-to-head SSRI versus TCA
 Outcome: 40 Global state: 1. CGI




Review: DCHP - Pharm - by drug class
 Comparison: 20 Head-to-head SSRI versus TCA
 Outcome: 41 Mental State: 1. Continuous measures - HAM-A




Review: DCHP - Pharm - by drug class
 Comparison: 20 Head-to-head SSRI versus TCA
 Outcome: 50 QoL: 1. Continuous measures




Review: DCHP - Pharm - by drug class
 Comparison: 20 Head-to-head SSRI versus TCA
 Outcome: 55 Physical health outcome: 1. MMSE - PD



Review: DCHP - Pharm - by drug class
 Comparison: 20 Head-to-head SSRI versus TCA
 Outcome: 60 Adverse events - reporting at least 1 adverse event




Review: DCHP - Pharm - by drug class
 Comparison: 20 Head-to-head SSRI versus TCA
 Outcome: 61 Adverse events - severe adverse event




SSRI versus placebo – sensitivity analysis removing non-blinded and subthreshold studies


Review: DCHP - Pharm - by drug class
 Comparison: 32 SSRIs versus placebo (Sensitivity analyses: Blinded/Non-blinded)
 Outcome: 01 Depression: 1. Not achieving success/ remission (reaching a specified cut-off) - observer rated




Review: DCHP - Pharm - by drug class
 Comparison: 32 SSRIs versus placebo (Sensitivity analyses: Blinded/Non-blinded)
 Outcome: 02 Depression: 2. Non-response (not achieving 50% reduction from baseline) - observer rated e.g. HAM-D, MADRS



Review: DCHP - Pharm - by drug class
 Comparison: 32 SSRIs versus placebo (Sensitivity analyses: Blinded/Non-blinded)
 Outcome: 03 Depression: 3. Patient-rated Continuous measures




Review: DCHP - Pharm - by drug class
 Comparison: 32 SSRIs versus placebo (Sensitivity analyses: Blinded/Non-blinded)
 Outcome: 04 Depression: 4. Observer-rated continuous measures




TCAs versus placebo – sensitivity analysis removing non-blinded and subthreshold studies

Review: DCHP - Pharm - by drug class
 Comparison: 33 TCAs versus placebo (Sensitivity analyses: Blinded/Non-blinded)
 Outcome: 02 Depression: 2. Non-response (not achieving 50% reduction from baseline) - observer rated e.g. HAMD, MADRS



Review: DCHP - Pharm - by drug class
 Comparison: 33 TCAs versus Placebo (Sensitivity analyses: Blinded/non-blinded)
 Outcome: 03 Depression: 3. Patient-rated continuous measures



Review: DCHP - Pharm - by drug class
 Comparison: 33 TCAs versus placebo (Sensitivity analyses: Blinded/Non-blinded)
 Outcome: 04 Depression: 4. Observer-rated Continuous measures

